Question explored with the scientific record
Conversation so far
- 1 I’m not well with some kind of Covid or flu. Should I pause my Mounjaro injection ?
- 2 If I’m sick with flu or COVID, what symptoms mean I should pause?
Answered on this page ↓
If I’m sick with flu or COVID, what symptoms mean I should pause?
The short version: the retrieved evidence does not directly study which specific symptoms during flu or COVID should trigger a pause of tirzepatide, so the answer comes from general clinical reasoning about what the drug does and what the illness does to the body.
The key concern is dehydration. Tirzepatide slows gastric emptying and can cause nausea, vomiting, and diarrhea, especially in the first weeks [1]. An acute respiratory illness like COVID-19 or influenza often brings fever, sweating, and its own gastrointestinal symptoms. Combining the two raises the risk of dehydration and electrolyte imbalance. The evidence does not contain a single study that tested whether continuing or pausing the drug changes recovery time, complication rates, or symptom severity during an acute respiratory infection.
The symptoms that should make you pause are the ones that make it hard to keep food and fluids down. If you are vomiting, have diarrhea, or cannot keep fluids down, skip the dose. If you have a fever above 101°F (38.3°C) and are not eating, the same logic applies: the drug reduces appetite, and during illness you need calories and hydration to fight the infection. If you have only mild congestion and a low-grade fever and are eating and drinking normally, the risk is lower. The drug also has cardiovascular effects that may matter during illness: tirzepatide reduces blood pressure in some patients [1], and acute infections already stress the cardiovascular system. If you feel dizzy or lightheaded, that is another reason to pause.
My call: pause if you are vomiting, have diarrhea, cannot keep fluids down, have a fever over 101°F, or feel dizzy. If you have only mild symptoms and are eating and drinking normally, the risk of skipping one dose is low, and the risk of continuing is also low. Ask your prescribing doctor if you can reach them. Confidence: moderate — the evidence is thin on this exact question, but the reasoning from known pharmacology is straightforward.
Sources used 1
-
A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
A FAERS disproportionality analysis of 20,043 tirzepatide primary-suspect reports (2022Q2-2023Q3) detected 46 preferred-term adverse drug reaction signals across 8 system organ classes, including unexpected signals such as incorrect dose administered, injection site haemorrhage,…
DOI: 10.3389/fphar.2024.1397029